Literature DB >> 30617303

The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity.

Shannon M White1, Shigekazu Murakami1, Chunling Yi2.   

Abstract

The Hippo-Yap/Taz pathway, originally identified as a central developmental regulator of organ size, has been found perturbed in many types of human tumors, and linked to tumor growth, survival, evasion, metastasis, stemness, and drug resistance. Beside these tumor-cell-intrinsic functions, Hippo signaling also plays important immune-regulatory roles. In this review, we will summarize and discuss recent breakthroughs in our understanding of how various components of the Hippo-Yap/Taz pathway influence the tumor immune microenvironment, including their effects on the tumor secretome and immune infiltrates, their roles in regulating crosstalk between tumor cells and T cells, and finally their intrinsic functions in various types of innate and adaptive immune cells. While further research is needed to integrate and reconcile existing findings and to discern the overall effects of Hippo signaling on tumor immunity, it is clear that Hippo signaling functions as a key bridge connecting tumor cells with both the adaptive and innate immune systems. Thus, all future therapeutic development against the Hippo-Yap/Taz pathway should take into account their multi-faceted roles in regulating tumor immunity in addition to their growth-regulatory functions. Given that immune therapies have become the mainstay of cancer treatment, it is also important to pursue how to manipulate Hippo signaling to boost response or overcome resistance to existing immune therapies.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30617303      PMCID: PMC7567008          DOI: 10.1038/s41388-018-0649-6

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  1 in total

1.  YAP regulates PD-L1 expression in human NSCLC cells.

Authors:  Jinbai Miao; Ping-Chih Hsu; Yi-Lin Yang; Zhidong Xu; Yuyuan Dai; Yucheng Wang; Geraldine Chan; Zhen Huang; Bin Hu; Hui Li; David M Jablons; Liang You
Journal:  Oncotarget       Date:  2017-12-09
  1 in total
  17 in total

1.  cTAZ: a safeguard factor of antiviral response.

Authors:  Sabrina Strano; Giovanni Blandino
Journal:  EMBO Rep       Date:  2019-04-17       Impact factor: 8.807

2.  A Yap-Myc-Sox2-p53 Regulatory Network Dictates Metabolic Homeostasis and Differentiation in Kras-Driven Pancreatic Ductal Adenocarcinomas.

Authors:  Shigekazu Murakami; Ivan Nemazanyy; Shannon M White; Hengye Chen; Chan D K Nguyen; Garrett T Graham; Dieter Saur; Mario Pende; Chunling Yi
Journal:  Dev Cell       Date:  2019-08-22       Impact factor: 12.270

3.  Sustained AWT1 expression by Dupuytren's disease myofibroblasts promotes a proinflammatory milieu.

Authors:  Johnny Luo; Trisiah Tugade; Emmy Sun; Ana Maria Pena Diaz; David B O'Gorman
Journal:  J Cell Commun Signal       Date:  2022-04-12       Impact factor: 5.782

Review 4.  The HIPPO pathway in gynecological malignancies.

Authors:  Dongying Wang; Jiaxing He; Junxue Dong; Thomas F Meyer; Tianmin Xu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

Review 5.  Hippo signalling in the liver: role in development, regeneration and disease.

Authors:  Jacquelyn O Russell; Fernando D Camargo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-21       Impact factor: 73.082

6.  Correction of the tumor suppressor Salvador homolog-1 deficiency in tumors by lycorine as a new strategy in lung cancer therapy.

Authors:  Zhe Zhao; Shufen Xiang; Jindan Qi; Yijun Wei; Mengli Zhang; Jun Yao; Tong Zhang; Mei Meng; Xiaohua Wang; Quansheng Zhou
Journal:  Cell Death Dis       Date:  2020-05-21       Impact factor: 8.469

7.  Interplay between cancer cells and M2 macrophages is necessary for miR-550a-3-5p down-regulation-mediated HPV-positive OSCC progression.

Authors:  Ming-Xin Cao; Wei-Long Zhang; Xiang-Hua Yu; Jia-Shun Wu; Xin-Wei Qiao; Mei-Chang Huang; Ke Wang; Jing-Biao Wu; Ya-Jie Tang; Jian Jiang; Xin-Hua Liang; Ya-Ling Tang
Journal:  J Exp Clin Cancer Res       Date:  2020-06-03

8.  KLF4 initiates sustained YAP activation to promote renal fibrosis in mice after ischemia-reperfusion kidney injury.

Authors:  Dan Xu; Pan-Pan Chen; Pei-Qing Zheng; Fan Yin; Qian Cheng; Zhuan-Li Zhou; Hong-Yan Xie; Jing-Yao Li; Jia-Yun Ni; Yan-Zhe Wang; Si-Jia Chen; Li Zhou; Xiao-Xia Wang; Jun Liu; Wei Zhang; Li-Min Lu
Journal:  Acta Pharmacol Sin       Date:  2020-07-09       Impact factor: 6.150

9.  YAP1 is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Pancreatic Cancer.

Authors:  Kai Sun; Xue-de Zhang; Xiao-Yang Liu; Pei Lu
Journal:  Front Mol Biosci       Date:  2021-06-02

10.  A novel lncRNA PLK4 up-regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP-mediated cell senescence.

Authors:  Yan Jia; Huanhuan Jin; Liyuan Gao; Xiang Yang; Feixia Wang; Hai Ding; Anping Chen; Shanzhong Tan; Feng Zhang; Jiangjuan Shao; Shijun Wang; Shizhong Zheng
Journal:  J Cell Mol Med       Date:  2020-04-03       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.